Zyprexa Zidis pills dispersible 5 mg 28 pieces
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Ingredients Olanzapine 5 mg Pharmacological action Antipsychotic agent (neuroleptic). Possesses affinity for serotonin 5-НТ2A / C-, 5-НТ3-, 5-НТ6-receptors. Dopamine D1, D2, D3, D4, D5 receptors. M1-5 cholinergic receptors. .1-adrenergic receptors and histamine H1 receptors. Shows antagonism against serotonin 5-NT-, dopamine and cholinergic receptors. In vitro and in vivo, it has a more pronounced affinity and activity for serotonin 5-HT2 receptors, compared with dopamine D2 receptors. According to electrophysiological studies, olanzapine selectively reduces the excitability of mesolimbic (A10) dopaminergic neurons and, at the same time, has little effect on striatal (A9) nerve pathways involved in the regulation of motor functions. Olanzapine reduces the conditioned defense reflex (a test that characterizes antipsychotic activity) at lower doses than is required to achieve catalepsy (a disorder reflecting a side effect on motor function). Unlike other neuroleptics, olanzapine enhances the anti-anxiety effect when conducting anxiolytic test. With the use of olanzapine, both productive (including delusions, hallucinations) and negative disorders are reduced.
Dosage and administration
Initial dose is 10-15 mg / day. The daily dose must be selected individually depending on the clinical condition of the patient. Therapeutic doses - 5-20 mg / day. Increasing the dose over the standard component (depending on the evidence) 10-15 mg / day is recommended only after an appropriate clinical examination of the patient. The dose should be increased gradually, at intervals of at least 24 hours. For elderly patients, as well as severe renal failure or liver failure of moderate severity, the initial dose is 5 mg / day. A reduction in the initial dose is recommended for patients with a combination of factors (female patients, old age, non-smokers) who may slow down the metabolism of olanzapine. Precautions During the period of treatment may worsen psoriasis. With pheochromocytoma, propranolol can be used only after taking an alpha blocker.After a long course of treatment, propranolol should be discontinued gradually, under the supervision of a physician. Against the background of treatment with propranolol, IV administration of verapamil, diltiazem should be avoided. A few days before anesthesia, you must stop taking propranolol or pick up a remedy for anesthesia with minimal negative inotropic effects. Influence on the ability to drive vehicles and control mechanisms In patients whose activities require increased attention, the question of the use of propranolol on an outpatient basis should be addressed only after evaluating the individual response of the patient. Side Effects From the side of the central nervous system: gait disturbance (in patients with dementia of the Alzheimer's type), drowsiness, akathisia, dizziness. seldom - convulsive seizures, ZNS. On the part of metabolism: weight gain, peripheral edema. On the part of the endocrine system: an increase in prolactin content (clinical manifestations of hyperprolactinemia were rarely observed, in most cases, the normalization of prolactin levels occurred without discontinuation of olanzapine). in rare cases - hyperglycemia, diabetic coma, diabetic ketoacidosis. Since the cardiovascular system: orthostatic hypotension. rarely bradycardia. On the part of the digestive system: constipation, dry mouth, increased appetite, increased activity of ALT and AST. rarely - hepatitis. Dermatological reactions: rarely - photosensitivity, rash. From the genitourinary system: rarely - priapism. From the hemopoietic system: eosinophilia. rarely - leukopenia, thrombocytopenia. Other: asthenia. Special instructions Use with extreme caution when increasing the activity of AST and ALT in patients with liver failure, limited functional reserve of the liver or in patients receiving treatment with potentially hepatotoxic drugs. In the event of an increase in AST and / or ALT activity during olanzapine treatment, careful monitoring of the patient is required, and, if necessary, dose reduction. Use with caution in patients with epileptic seizures in history or exposed to factors that reduce the threshold of convulsive readiness. Use with caution in patients with low white blood cell count and / or neutrophil count.due to various reasons. with signs of oppression / toxic impairment of bone marrow function under the influence of drugs in history. with inhibition of bone marrow function due to concomitant disease, radiotherapy or chemotherapy in history. with hypereosinophilia or myeloproliferative disease. In clinical studies, the use of olanzapine in patients with clozapine-dependent neutropenia or agranulocytosis in a history of disease was not accompanied by a relapse of these disorders. Use with caution in patients with clinical manifestations of prostatic hyperplasia, paralytic intestinal obstruction, angle-closure glaucoma and similar conditions. The treatment of neuroleptics, including olanzapine, may develop NNS. Clinical manifestations of MNS or a significant increase in body temperature without the other symptoms of this syndrome require the abolition of all neuroleptics, including olanzapine. With prolonged therapy with neuroleptics, there is a risk of tardive dyskinesia. If signs of tardive dyskinesia develop, a dose reduction or elimination of olanzapine is recommended. Symptoms of tardive dyskinesia may appear or increase after discontinuation of therapy. Given the nature of the effect of olanzapine on the central nervous system, it should be used with caution in combination with other drugs of central action and ethanol. The safety and efficacy of olanzapine in patients under the age of 18 years have not been studied. Influence on the ability to drive motor vehicles and work with mechanisms During the period of treatment should be wary of engaging in activities related to the need for concentration and high-speed psychomotor reactions. Use during pregnancy and breastfeeding Adequate and strictly controlled clinical studies of the safety of using olanzapine during pregnancy have not been conducted. Application is possible only in cases where the expected benefit of therapy for the mother greatly exceeds the potential risk to the fetus. Currently, there are no data on the release of olanzapine in breast milk. If necessary, use during lactation breastfeeding should be discontinued.Type: Medicine Quantity in the package, pcs: 28 Shelf life: 24 months Active ingredient: Olanzapine (Olanzapine) Route of administration: Oral Vacation schedule: Prescription Release form: Prescription Storage conditions: In a dry place, In a dark place, Keep out of reach of children Maximum storage temperature, ° С: 20 Pharmacological group: N05AH03 Olanzapine Minimum age: 18 yearsActive ingredients
Olanzapine
Release form
Pills
Composition
Olanzapine 5 mg
Pharmacological effect
Antipsychotic (neuroleptic). Possesses affinity for serotonin 5-НТ2A / C-, 5-НТ3-, 5-НТ6-receptors. Dopamine D1, D2, D3, D4, D5 receptors. M1-5 cholinergic receptors. & # 945 .1-adrenergic receptors and histamine H1 receptors. Shows antagonism against serotonin 5-NT-, dopamine and cholinergic receptors. In vitro and in vivo, it has a more pronounced affinity and activity for serotonin 5-HT2 receptors, compared with dopamine D2 receptors. According to electrophysiological studies, olanzapine selectively reduces the excitability of mesolimbic (A10) dopaminergic neurons and, at the same time, has little effect on striatal (A9) nerve pathways involved in the regulation of motor functions. Olanzapine reduces the conditioned defense reflex (a test that characterizes antipsychotic activity) at lower doses than is required to achieve catalepsy (a disorder reflecting a side effect on motor function). Unlike other neuroleptics, olanzapine enhances the anti-anxiety effect when conducting anxiolytic test. With the use of olanzapine, both productive (including delusions, hallucinations) and negative disorders are reduced.
Indications
Treatment of exacerbations, supportive and long-term anti-relapsing therapy for schizophrenia and other psychotic disorders with pronounced productive (including delusions, hallucinations, automatism) and / or negative (including emotional flattening, decrease in social activity, impoverishment of speech) symptoms, as well as concomitant affective disorders. Treatment of acute manic or mixed episodes in bipolar affective disorder with / without psychotic manifestations and with / without rapid phase change.
Contraindications
Hypersensitivity to olanzapine.
Use during pregnancy and lactation
Adequate and strictly controlled clinical studies on the safety of olanzapine in pregnancy have not been conducted. Application is possible only in cases where the expected benefit of therapy for the mother greatly exceeds the potential risk to the fetus. Currently, there are no data on the release of olanzapine in breast milk. If necessary, use during lactation breastfeeding should be discontinued.
Dosage and administration
The initial dose is 10-15 mg / day. The daily dose must be selected individually depending on the clinical condition of the patient. Therapeutic doses - 5-20 mg / day. Increasing the dose over the standard component (depending on the evidence) 10-15 mg / day is recommended only after an appropriate clinical examination of the patient. The dose should be increased gradually, at intervals of at least 24 hours. For elderly patients, as well as severe renal failure or liver failure of moderate severity, the initial dose is 5 mg / day. A reduction in the initial dose is recommended for patients with a combination of factors (female patients, old age, non-smokers) who may slow down the metabolism of olanzapine.
Side effects
From the side of the central nervous system: violation of gait (in patients with dementia of the Alzheimer's type), drowsiness, akathisia, dizziness. seldom - convulsive seizures, ZNS. On the part of metabolism: weight gain, peripheral edema. On the part of the endocrine system: an increase in prolactin content (clinical manifestations of hyperprolactinemia were rarely observed, in most cases, the normalization of prolactin levels occurred without discontinuation of olanzapine). in rare cases - hyperglycemia, diabetic coma, diabetic ketoacidosis. Since the cardiovascular system: orthostatic hypotension. rarely bradycardia. On the part of the digestive system: constipation, dry mouth, increased appetite, increased activity of ALT and AST. rarely - hepatitis. Dermatological reactions: rarely - photosensitivity, rash. From the genitourinary system: rarely - priapism. From the hemopoietic system: eosinophilia. rarely - leukopenia, thrombocytopenia. Other: asthenia.
special instructions
From the side of the central nervous system: violation of gait (in patients with dementia of the Alzheimer's type), drowsiness, akathisia, dizziness. seldom - convulsive seizures, ZNS. On the part of metabolism: weight gain, peripheral edema. On the part of the endocrine system: an increase in prolactin content (clinical manifestations of hyperprolactinemia were rarely observed, in most cases, the normalization of prolactin levels occurred without discontinuation of olanzapine). in rare cases - hyperglycemia, diabetic coma, diabetic ketoacidosis. Since the cardiovascular system: orthostatic hypotension. rarely bradycardia. On the part of the digestive system: constipation, dry mouth, increased appetite, increased activity of ALT and AST. rarely - hepatitis. Dermatological reactions: rarely - photosensitivity, rash. From the genitourinary system: rarely - priapism. From the hemopoietic system: eosinophilia. rarely - leukopenia, thrombocytopenia. Other: asthenia.